Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial.

What is known: Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. Crocus sativus (saffron) may inhibit the aggregation and deposition of amyloid β in the human brain and may therefore be useful in Alzheimer’s disease (AD...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Pharmacy & Therapeutics Vol. 35; no. 5; pp. 581 - 589
Autores principales: Akhondzadeh, S., Sabet, M. Shafiee, Harirchian, M. H., Togha, M., Cheraghmakani, H., Razeghi, S., Hejazi, S. Sh., Yousefi, M. H., Alimardani, R., Jamshidi, A., Zare, F., Moradi, A.
Formato: clinical trial research tables/charts Journal Article
Publicado: Wiley-Blackwell Oct2010
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=53541375&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 53541375
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02694727
        EV4
      jtl: Journal of Clinical Pharmacy & Therapeutics
      issn: 02694727
      maglogo: Y
    pubinfo:
      dt: Oct2010
      vid: 35
      iid: 5
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        53541375
        105099228
        105099228
        10.1111/j.1365-2710.2009.01133.x
        53541375
      ppf: 581
      ppct: 8
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial.
      aug:
        au:
          Akhondzadeh, S.
          Sabet, M. Shafiee
          Harirchian, M. H.
          Togha, M.
          Cheraghmakani, H.
          Razeghi, S.
          Hejazi, S. Sh.
          Yousefi, M. H.
          Alimardani, R.
          Jamshidi, A.
          Zare, F.
          Moradi, A.
        affil: ‡Department of Neurology, Tehran University of Medical Sciences, Tehran
      sug:
        subj:
          Alzheimer's Disease Drug Therapy
          Plants, Medicinal Therapeutic Use
          Human
          Double-Blind Studies
          Alzheimer's Disease Physiopathology
          Iran
          Middle Age
          Aged
          Scales
          Psychological Tests
          Random Assignment
          Repeated Measures
          Analysis of Variance
          T-Tests
          Fisher's Exact Test
          Descriptive Statistics
          Male
          Female
          Alternative Therapies
          Funding Source
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: What is known: Herbal medicines have been used in the treatment of behavioural and psychological symptoms of dementia but with variable response. Crocus sativus (saffron) may inhibit the aggregation and deposition of amyloid β in the human brain and may therefore be useful in Alzheimer’s disease (AD). Objective: The goal of this study was to assess the efficacy of saffron in the treatment of mild to moderate AD. Methods: Forty-six patients with probable AD were screened for a 16-week, double-blind study of parallel groups of patients with mild to moderate AD. The psychometric measures, which included AD assessment scale-cognitive subscale (ADAS-cog), and clinical dementia rating scale-sums of boxes, were performed to monitor the global cognitive and clinical profiles of the patients. Patients were randomly assigned to receive capsule saffron 30 mg/day (15 mg twice per day) (Group A) or capsule placebo (two capsules per day) for a 16-week study. Results: After 16 weeks, saffron produced a significantly better outcome on cognitive function than placebo (ADAS-cog: F = 4·12, d.f. = 1, P = 0·04; CDR: F = 4·12, d.f. = 1, P = 0·04). There were no significant differences in the two groups in terms of observed adverse events. What is new and conclusion: This double-blind, placebo-controlled study suggests that at least in the short-term, saffron is both safe and effective in mild to moderate AD. Larger confirmatory randomized controlled trials are called for.
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N